Morgan Stanley raised the firm’s price target on Omada Health (OMDA) to $32 from $30 and keeps an Overweight rating on the shares. Q3 revenue increased 49% year-over-year and beat by 11%, and the company crossed the threshold to EBITDA profitability, the analyst tells investors in a research note. The firm added that momentum continues, and the big development on the quarterly call was expanding its GLP-1 offering to include prescribing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health price target raised to $28 from $27 at Evercore ISI
- Omada Health, Inc.: Strong Revenue Momentum and Strategic Partnerships Drive Buy Rating
- Omada Health, Inc.: Strong Market Position and Growth Potential Drive Buy Rating
- Omada Health price target raised to $29 from $28 at Barclays
- Omada Health Reports Strong Q3 2025 Growth